Lead Sponsor

Genzyme, a Sanofi Company

Age

All ages

Sex

MALE

Healthy Volunteers

No

•The participant and/or his parent/legal guardian is willing and able to provide signed informed consent, and the participant, if less than (\<) 18 years of age, is willing to provide assent if deemed able to do so
•Participant is male and has been treated with agalsidase alfa at 0.2 mg/kg q2w for the 12 months prior to switching to agalsidase beta
•The participant has a confirmed diagnosis of Fabry disease by alfa-galactosidase A (alfa-GAL) activity and/or genotyping per local standards
•The participant when switched to agalsidase beta receives the labeled dose, that is, 0.9 to 1.1 mg/kg (1 mg/kg) q2w, and must be willing to maintain the labeled dose for the duration of the study

•The participant is on dialysis or is post renal transplantation
•The participant is in end-stage cardiac failure
•The participant and/or his parent or legal guardian, in the opinion of the investigator, is unable to adhere to the requirements of the study
•The participant has been switched from agalsidase alfa to agalsidase beta and does not have historical blood and urine samples

Related studies

NCT06328608 · Fabry Disease

NCT06941025 · Fabry Disease, Pregnancy, and more

NCT06539624 · Fabry Disease

NCT06935578 · CADASIL, CADASIL (Diagnosis), and more

NCT04440254 · Fabry Disease

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta